title: Validation of the cantharidin-induced skin blister as an in vivo model of inflammation.
abstract: OBJECTIVE
  Pharmacological profiling techniques, such as the cantharidin-induced skin blister, may be used to assess the anti-inflammatory properties of novel drugs. However, no data are available on the reproducibility of this technique or on the blocking effect of anti-inflammatory drugs, such as anti-TNF and corticosteroids.
  
  
  METHODS
  A group of 30 healthy subjects were randomized into three parallel groups treated with placebo, oral methylprednisolone 20 mg day(-1) for 7 days or anti-tumour necrosis factor (TNF) (adalimumab, Humira®, Abbott) 40 mg s.c. single dose. A first blister was induced at baseline and collected, immediately before the start of treatment and a second blister was obtained 7 days after the start of treatment. The total number of cells, the cell viability and the differential cell count were evaluated by two independent observers, who were blind to treatment. anova was used to compare change from baseline among the three groups before pairwise comparisons.
  
  
  RESULTS
  Among the placebo group, there was no significant difference in the total cell count, neutrophils, eosinophils and monocytes between day 1 and day 7. Methylprednisolone inhibited the eosinophil influx in mean % (95% CI) (-1.0 (-1.7, -0.3); P < 0.02) and absolute (P < 0.02) values, while anti-TNF inhibited the neutrophil influx in mean % (95% CI) (-19.3 (-29.5, -9.1); P < 0.01) and absolute (P < 0.05) values.
  
  
  CONCLUSIONS
  The cantharidin-induced skin blister is a safe, well tolerated and reproducible procedure. Pre-treatment with anti-TNF or methylprednisolone inhibited the neutrophilic or eosinophilic trafficking, respectively. It could be useful in profiling anti-inflammatory drugs regarding their effects on the cellular inflammatory response.
authors: Clinic of Immuno-allergology, CHU Brugmann (Université Libre de Bruxelles), Brussels, Belgium.
authors: Phong Huy Duc
authors: PH
authors: Dinh
authors: Francis
authors: F
authors: Corraza
authors: Kristel
authors: K
authors: Mestdagh
authors: Zaina
authors: Z
authors: Kassengera
authors: Virginie
authors: V
authors: Doyen
authors: Olivier
authors: O
authors: Michel
references: J Immunol Methods. 2001 Nov 1;257(1-2):213-20
references: 11687254
references: Br J Clin Pharmacol. 1998 Nov;46(5):425-31
references: 9833594
references: J Clin Pathol. 1971 Oct;24(7):633-5
references: 4940806
references: Proc Natl Acad Sci U S A. 2010 May 11;107(19):8842-7
references: 20421472
references: Am J Pathol. 1964 Jan;44:61-71
references: 14103202
references: Ann N Y Acad Sci. 1955 Mar 24;59(5):757-805
references: 13259351
references: Respir Res. 2004 Nov 02;5:18
references: 15522115
references: Antimicrob Agents Chemother. 2003 May;47(5):1771-3
references: 12709358
references: Lancet. 1986 Feb 8;1(8476):307-10
references: 2868172
references: Int J Antimicrob Agents. 2003 Jul;22(1):77-80
references: 12842333
references: J Endotoxin Res. 2001;7(5):385-8
references: 11753208
references: Lancet. 1964 Jun 27;2(7348):1444-5
references: 14149183
references: Circ Res. 2004 Jan 9;94(1):119-26
references: 14656926
references: Arch Dermatol. 1998 Jan;134(1):104-6
references: 9449922
references: J Immunol. 2009 Aug 1;183(3):2089-96
references: 19597002
references: Aliment Pharmacol Ther. 2006 Aug 15;24(4):651-60
references: 16907898
references: Clin Immunol. 2008 Feb;126(2):121-36
references: 17916444